Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

Amgen (AMGN) stock is in focus as its cholesterol drug Repatha succeeds in a Phase 3 trial, reducing the risk of major adverse cardiovascular events. Read more here.

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.

Dr. Roach: I had a pituitary tumor that was discovered over 25 years ago. For years, I had an MRI with and without dye every six months. Then it changed to once a year. Can you get damage from too ...